Amgen Inc header image

Amgen Inc

AMGN

Equity

ISIN null / Valor 907582

NASDAQ (2026-11-06)
USD 460.42+0.03%

Amgen Inc
UMushroom community rating:

star star star star star
4.09 12 votes No rating yet
NegativeNeutralPositive

About company

Amgen Inc. is a global biopharmaceutical company based in Thousand Oaks, California, that discovers, develops, manufactures and markets protein- and antibody-based therapies for serious illnesses; its commercial portfolio and pipeline focus on areas such as oncology, hematology and supportive care, nephrology, bone disease, cardiovascular disease and inflammation, and it also participates in the biosimilars market. The company’s business model combines research and late-stage development of biologics with in-house manufacturing and global commercial operations, with well-known marketed products that have included Epogen and Neulasta (supporting hematologic indications), Enbrel (inflammatory disease), Repatha (cardiovascular risk) and Prolia/Xgeva (bone health). Amgen is publicly traded and derives the bulk of its revenue from therapeutic product sales while continuing to invest in R&D to replenish and expand its pipeline.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

45.9%1Y
68.8%3Y
115%5Y

Performance

29.4%1Y
27.3%3Y
24.9%5Y

Volatility

Market cap

249046 M

Market cap (USD)

Daily traded volume (Shares)

2,579,691

Daily traded volume (Shares)

1 day high/low

261.55 / 258.74

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.09

12 votes
Performance:
starstarstarstarstar
3.88
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
3.73
Nature:
starstarstarstarstar
3.37
Nafi Mohammed
UK, 08 Nov 2026
star star star star star
+42% YTD, strong biotech pipeline, 2.1% dividend. P/E compresses to ~19x on forward EPS. Analysts see slight near-term downside but long-term fundamentals solid.
Jaehan Neoh
UK, 07 Nov 2026
star star star star star
good
Athish Manjunath
UK, 07 Nov 2026
star star star star star
Awesome

EQUITIES OF THE SAME SECTOR

Biogen Inc
Biogen Inc Biogen Inc Valor: 1720684
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.81%USD 248.35
Zydus Lifesciences Limited
Zydus Lifesciences Limited Zydus Lifesciences Limited Valor: 29835501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%INR 1,195.00
IPCA Laboratories Limited
IPCA Laboratories Limited IPCA Laboratories Limited Valor: 115718957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%INR 1,942.95
AnaptysBio, Inc.
AnaptysBio, Inc. AnaptysBio, Inc. Valor: 29675116
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.91%USD 46.45
LeMaitre Vascular inc
LeMaitre Vascular inc LeMaitre Vascular inc Valor: 2755054
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.11%USD 80.89
GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.16%USD 50.33
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited Valor: 3195888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%INR 2,592.85
GSK PLC
GSK PLC GSK PLC Valor: 119642297
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 18.90
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.77%GBP 16.50
Piramal Pharma Limited
Piramal Pharma Limited Piramal Pharma Limited Valor: 114197705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.17%INR 239.20